NEW YORK, July 11 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. , Forest Laboratories Holdings, Ltd. and H. Lundbeck A/S announced that they have filed a lawsuit in the U.S. District Court for the Eastern District of Michigan against Caraco Pharmaceutical Laboratories, Ltd. for infringement of U.S. Patent Re. No. 34,712, which relates to Forest’s Lexapro(R) product.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Forest has received notification from Caraco Pharmaceutical Laboratories, Ltd. that it filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV Certification for a generic equivalent to Lexapro(R).
Howard Solomon, Chairman and Chief Executive Officer of Forest, said: “We believe the patent on Lexapro is valid and enforceable. Just as we did in our prior patent litigations against Ivax Pharmaceuticals and Alphapharm, we intend to prosecute this lawsuit vigorously.”
Except for the historical information contained herein, this release contains “forward-looking statements” within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories’ SEC reports, including the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2006.
Photo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGOForest Laboratories, Inc.
CONTACT: Charles E. Triano, Vice President-Investor Relations of ForestLaboratories, Inc., +1-212-224-6714, charles.triano@frx.com
Web site: http://www.frx.com/
